Cassava Sciences presented new data at CTAD23 that show “without a doubt” that simufilam does not work, STAT’s Adam Feuerstein reports. “I appreciate the transparency of the presentation, it was much more informative than press release from the summer,” Feuerstein said via a post on X, formerly Twitter. “The new data today also show without a doubt that simufilam does not work. I’ll have more details later.” Cassava shares are down over 5% in after-hours trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAVA:
- Biotech Alert: Searches spiking for these stocks today
- Cassava Sciences call volume above normal and directionally bullish
- MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
- Cassava Sciences says MRI data suggests simufilam not associated with ARIA
- Cassava Sciences put volume heavy and directionally bearish